Roche: European Commission approves vabysmo

(CercleFinance.com) - Today Roche announced that the European Commission has approved vabysmo (faricimab) for the treatment of neovascular or wet age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME).


These retinal conditions are two of the leading causes of vision loss worldwide, affecting over 40 million people.

Vabysmo is the only injectable eye medication approved in Europe with Phase III studies supporting treatment at intervals of up to four months for people living with NAMD and DME. With the potential to require fewer eye injections over time, while improving and maintaining vision and anatomy, Vabysmo could offer a less burdensome treatment schedule for individuals, their caregivers and healthcare systems.



Copyright (c) 2022 CercleFinance.com. All rights reserved.